Skip to main content
Premium Trial:

Request an Annual Quote

Rodman & Renshaw Upgrades Rating on Sequenom's Stock

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment firm Rodman & Renshaw has upgraded Sequenom's stock to "Market Perform" from "Market Underperform" following yesterday's publication by the San Diego-based firm of results on its non-invasive fetal trisomy 21 test.

According to a study published in the online edition of the American Journal of Obstetrics and Gynecology, the overall classification showed 100 percent sensitivity and 99.7 percent specificity.

In a research note, Elemer Piros, an analyst at Rodman & Renshaw, wrote, "The bottom line in our view is that the reported test performance appears to be commercially acceptable, which is why we believe that this announcement reduces the scientific risk associated with the T21 test."

While he upgraded Sequenom's stock, he did not place a new price target on the shares, saying he has concerns about the commercial value of the test. Rodman & Renshaw had earlier placed a $5 target on the stock.

While the study demonstrates the T21 test "appears to be clinically sufficient we believe that the overall throughput and costs of 'shotgun sequencing' may present a problem," he wrote. According to Sequenom's 4-plexing studies, Piros said, each sample analysis would take two days to complete on a sequencer.

Piros estimated that in order to scale up to process 500,000 to 1 million samples per year, about 1,000 sequencers would be required, costing between $500 million and $600 million. However, he noted that Sequenom "would not have to acquire all the capital equipment upfront, and could build-out the lab as demand grows."

In Friday morning trade on the Nasdaq, shares of Sequenom were up 1 percent at $7.29.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.